Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Inflammatory biomarkers in Alzheimer's disease plasma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer's disease-A cohort study of 95,442 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Polyols and Branched Chained Amino Acids Are Associated with Present and Future Renal Impairment in Type 1 Diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Circulating metabolites are associated with present and future renal impairment in type 1 Diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Low carbohydrate diet elevates blood sphingomyelin in people with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. Renal function dominates the landscape of the metabolome in type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • NIMA Consortium
View graph of relations

INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.

METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.

RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).

DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Original languageEnglish
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Volume15
Issue number6
Pages (from-to)776-787
Number of pages12
ISSN1552-5260
DOIs
Publication statusPublished - 1 Jun 2019
Externally publishedYes

Bibliographical note

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

    Research areas

  • Alzheimer's disease, Biomarker, Complement, Inflammation, Plasma

ID: 57306877